Clinical effectiveness of defibrotide in vaso-occlusive disorders and its mode of actions.
Ulutin
O N
ON
Department of Medicine, Cerrahpasa Medical School, Istanbul University, Turkey.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000792:Angiography; D001161:Arteriosclerosis / Q000188:drug therapy*; D000242:Cyclic AMP / Q000097:blood; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D011089:Polydeoxyribonucleotides / Q000494:pharmacology / Q000627:therapeutic use*; D013919:Thromboangiitis Obliterans / Q000188:drug therapy*; D013929:Thromboxane B2 / Q000097:blood
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D000242:Cyclic AMP